| abstract |
Described is an arylalkylthiadiazinone derivative of formula (I) wherein R 1 is H, R 2 is H or A, R 3 is OH, -OR 10, -NHR 10 or -NR 10 R 11, R 4 is OH or -OR 10, R 5 is phenyl optionally substituted with 1 or 2 R6 and / or R7, Q is absent or is C1-6alkylene, R6 and R7 are each independently -NH2, -NR8R9, -NO2, -OA, -COOH or -COOA, R9 and R9 are each from independently H, C 1-8 alkyl optionally substituted with 1 to 5 F and / or Cl, -COOA, -SO 2 -A, -CONH 2, -CONHA, -CONA 2, -CO-COOH, -CO-COOA, -CO- CONH 2, -CO-CONHA or -CO-CONA 2, A is C 1-6 alkyl optionally substituted with 1 to 5 F and / or Cl, R 10 and R 11 are each independently A, C 3-7 cycloalkyl or methylene-C 4-8 cycloalkyl, and the physiologically acceptable salt inhibits phosphodiesterase IV and is therefore useful in the manufacture of pharmaceutical compositions for the treatment of asthmatic diseases and is equally useful as an intermediate for the treatment of asthmatic diseases. robu dalšíà |